BACK of the BOOK
Heard in the Blogosphere
ASH
@ASH_Hematology
Q1: If you had to name
a top advance in lymphoma care and treatment
in the past few years,
what would it be?
#ASHMHM15
Jorge Cham, PhD
@PhDComics
Academic deadlines
Jodi G. Daniel, JD, MPH
@JodiDaniel
John P. Leonard, MD
@JohnPLeonardMD
We need clear metrics on drug “financial toxicity” - need
to quantify and incorporate into study design in useful way
#ASHMHM15
Miguel Perales, MD
@DrMiguelPerales
A1: Challenge of novel therapies in #lymphoma will be
prioritizing sequencing combining (cost) etc. - good problem
to have #lysm #ASHMHM15
Susannah E. Koontz, PharmD, BOCP
@KoontzOncology
A1: Yes! Factors such as ADRs and #financialtoxicity will be key
especially in the elderly #lymphoma patient #ASHMHM15
We tolerate risk in many aspects of our life. Health care should
not be different. Patients can make decisions about health.
Michael Fisch, MD
@fischmd
“You can’t rush a miracle.
You get a lousy miracle.”
– Miracle Max from “The
Princess Bride.” [from a
colleague analyzing a
large dataset]
Weill Cornell
@WeillCornell
Donning their white coats yesterday,
#WCMC2019 students are ready to put
the patient at center of everything they do
74
ASH Clinical News
September 2015